– At Magellan, we are committed to remaining on the forefront of developments in the emerging growth areas of biomedical research and clinical diagnostics. We believe we are uniquely positioned to translate discoveries in the research market, such as novel , into new products that enable earlier, more accurate diagnosis and treatment of disease. We continue to innovate, and are enabling applications never-before possible. For example, click here to read about the exciting work enabled by 's new ®.
In recognition of the breakthroughs ESA has achieved with Corona and our pioneering work in , in March 2005, we were awarded a major grant under the highly competitive National Institutes of Health for Medical Research initiative directed at new technologies for metabolomics. The grant will accelerate the important work ESA has undertaken toward developing a rugged platform that will combine two powerful tools for medical research – electrochemical (EC) detection and mass spectrometry (MS). We believe this will substantially extend the scope, qualitative, and quantitative capabilities of liquid-chromatographic (LC) analysis of cellular metabolites.
As part of the Roadmap grant, ESA will collaborate with a number of leading institutions, including: Oak Ridge National Laboratory, Applied Biosystems/MDS SCIEX, Millennium Pharmaceuticals, Cornell University Medical School, Massachusetts College of Pharmacy, Boston University Medical School, and Burke Medical Research Institute.
ESA is also a leading manufacturer of analyzers used in physician's offices and other clinical and laboratory setting for measuring lead levels in blood. We are exploring the possibility of extending the electrochemistry detection technology we use in these devices to additional point-of-care applications. |
